UCB SA (VIE:UCB)
Austria
· Delayed Price · Currency is EUR | Market Cap | 43.35B |
| Revenue (ttm) | 7.74B |
| Net Income (ttm) | 1.56B |
| Shares Out | n/a |
| EPS (ttm) | 8.03 |
| PE Ratio | 27.82 |
| Forward PE | 21.12 |
| Dividend | 1.02 (0.41%) |
| Ex-Dividend Date | May 4, 2026 |
| Volume | n/a |
| Average Volume | 8 |
| Open | 239.60 |
| Previous Close | 242.70 |
| Day's Range | 236.00 - 239.60 |
| 52-Week Range | 149.25 - 288.60 |
| Beta | n/a |
| RSI | 34.02 |
| Earnings Date | Jul 30, 2026 |
About UCB SA
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson’s disease and restless legs syndrome. It also provides Nayzilam, a nasal spray rescue treatment for... [Read more]
Financial Performance
In 2025, UCB SA's revenue was 7.74 billion, an increase of 25.83% compared to the previous year's 6.15 billion. Earnings were 1.56 billion, an increase of 46.29%.
News
Belgium's UCB in autoimmune drug deal with Antengene
Belgian drugmaker UCB has entered into an agreement to licence Antengene's experimental autoimmune disease therapy ATG-201 and associated technology, paying $60 million up front and over $1.1 billio...
U.S. FDA approves KYGEVVI® (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d)
Approved indication: KYGEVVI® (doxecitine and doxribtimine) powder for oral solution (2g/2g) is approved for the treatment of thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients with...